“Fast but not so furious”: A condensed step‐up dosing schedule of teclistamab for relapsed/refractory multiple myeloma

Abstract Teclistamab is a B‐cell maturation antigen (BCMA)‐directed bispecific T‐cell engager approved for relapsed‐refractory multiple myeloma (RRMM). Cytokine release syndrome (CRS) and Immune effector cell‐associated neurotoxicity syndrome (ICANS) are well‐documented treatment ‐related adverse ev...

Full description

Bibliographic Details

Published in:	eJHaem
Main Authors:	Kevin C. Graf, James A Davis, Alyssa Cendagorta, Katelynn Granger, Kelly J. Gaffney, Kimberly Green, Brian T Hess, Hamza Hashmi
Format:	Article
Language:	English
Published:	Wiley 2024-08-01
Subjects:	immunotherapy multiple myeloma myeloma therapy
Online Access:	https://doi.org/10.1002/jha2.906